[1] Johnson C, Ivanisevic J, Siuzdak G, et al. Metabolomics: beyond biomarkers and towards mechanisms[J]. Nat Rev Mol Cell Biol, 2016,17:451-459. [2] Li L, Zheng X, Zhou Q, et al. Metabolomics based discovery of molecular signatures for triple negative breast cancer in asian female population[J]. Sci Rep, 2020,10:370-372. [3] Dong Y, Arif AA, Guo J, et al. CD44 loss disrupts lung lipid surfactant homeostasis and exacerbates oxidized lipid-induced lung inflammation[J]. Front Immunol, 2020,11: 29-35. [4] Fenaille P, Hilaire K, Rousseau, et al. Data acquisition workflows in liquid chromatography coupled to high resolution mass spectrometrybased metabolomics: where do we stand?[J]. J Chromatogr A, 2017,1526:1-12. [5] Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine[J]. Nat Rev Drug Discov, 2016, 15:473-484. [6] Beyer B, Fang M, Sadrian B, et al. Metabolomics-based discovery of a metabolite that enhances oligodendrocyte maturation[J]. Nat Chem Biol, 2018, 14:22-28. [7] Rinschen M, Ivanisevic J, Giera M, et al. Identification of bioactive metabolites using activity metabolomics[J]. Nat Rev Mol Cell Biol, 2019, 20:353-367. [8] Warth B, Spangler S, Fang M, et al. Exposome-scale investigations guided by global metabolomics, pathway analysis, and cognitive computing[J]. Anal Chem, 2017, 89:11505-11513. [9] Zhu X, Chen Y, Subramanian R. Comparison of information-dependent acquisition,SWATH, and MSAll techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole timeof-flight mass spectrometry[J]. Anal Chem, 2014, 86:1202-1209. [10] Guo J, Huan T. Comparison of full-scan, data-dependent, and data independent acquisition modes in liquid chromatography mass spectrometry based untargeted metabolomics[J]. Anal Chem, 2020,92:8072-8080. |